This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2013.
For an indepth analysis of these deals, read ‘Pharma deals during November 2013’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Viropharm / Shire | Acquisition | Orphan drugs including Cinryze for prophylactic treatment of hereditary angioedema |
4,200 |
| Santarus / Salix | Acquisition | Portfolio of approved products in GI, diabetes and Hyperlipidemia |
2,600 |
| Algeta / Bayer | Acquisition | Buys out deal for Xofigo radiotherapeutic for prostate cancer |
2,400 |
| Pfizer / Lilly | Co-development | Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain | 1,800 |
| Novartis / Grifols | Acquisition | Novartis divestment of its blood transfusion testing unit | 1,675 |
| Paladin / Endo Health | Acquisition | Portfolio includes products in attention deficit hyperactivity disorder, pain, urology and allergy |
1,600 |
| immatics / Roche | R&D and commercialisation |
IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer | 1,017 |
| Patheon / Royal DSM and JLL Partners | Merger and acquisition | DSM and JLL Partners (private equity) acquire Patheon and merge it with DSM’s CMO Pharmaceutical Products Division in a jointly owned Newco |
582 |
| Polyphor / Roche | Licence | POL7080 which targets Pseudomonas aeruginosa, completed phase I | 548 |
| Cytori/Lorem Vascular |
Licence | Cell therapy for CVS, diabetes, and renal disease includes equity purchase |
531 |
| Vital Signs/ CareFusion |
Acquisition | Vital Signs is the respiratory care and anesthesiology product manufacturer division of GE Healthcare | 500 |
| Clovis / Servier | Licence | Servier licenses lucitanib excluding China, Japan and the US | 475 |
| Egalet /Shionogi | Licence | Oral abuse-deterrent hydrocodone opioid products includes an equity purchase | 425 |
| EOS /Clovis | Acquisition | Lucitanib for FGF aberrant breast cancer | 420 |
| BeiGene / Merck Serono |
Co-development | Expansion of collaboration to include BeiGene 290 for cancer | 232 |
| Cell Therapeutics / Baxter | Licence | JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase | 172 |
| Vertex / Janssen | Royalty sale | Sale of product royalty rights relating to INCIVO (telaprevir) to Janssen Pharmaceutica | 152 |
| Calidus / Amicus | Acquisition | Purchase of Callidus’ late-stage enzyme replacement therapy for Pompe disease | 130 |
| Evotec /Janssen | R&D collaboration | Target AD collaboration to identify novel therapies for Alzheimer’s | 125 |
| Merck & Co / Akorn | Product acquisition | US rights to AzaSite, Cosopt, Cosopt PF ophthalmic products | 52.8 |